{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:51:01Z","timestamp":1792180261307,"version":"4.4.0"},"reference-count":84,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec id=\"ab-crv250006-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>It has been stated that especially with the advancements in imaging, systemic therapy, and local radical treatment (LRT) that patients with synchronous oligometastatic disease (sOMD) can potentially benefit from curative-intent treatment. This statement is challenged by the results of the NRG-LU002 randomized phase 2\/3 trial, showing no significant progression-free survival and overall survival improvements with the addition of LRT to maintenance systemic therapy in patients with oligometastatic non\u2013small cell lung cancer (NSCLC) who achieved at least stable disease after induction systemic therapy (approximately 90% received an immunotherapy-based regimen). This Review discusses the current challenges and controversies in the treatment of non\u2013oncogene-addicted sOMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv250006-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Whether LRT indeed can improve survival in a contemporary immunotherapy-based systemic treatment regimen is discussed as well as the optimal treatment sequence. Moreover, the NRG-LU002 trial also sparks debate of whether a true sOMD state exists. Genomic alterations, the tumor microenvironment of the primary tumor and metastasis, organotropism, and tumor heterogeneity can all influence metastatic potential, giving a biological explanation that there could be existence of a true sOMD state. However, as true sOMD cannot be distinguished from early-detected widespread metastatic disease with the current imaging modalities, it becomes difficult to select patients for a radical strategy and protect patients from futile treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv250006-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>It remains under debate whether synchronous oligometastatic NSCLC represents a distinct biological entity or merely a probabilistic imaging finding. Biomarkers such as circulating tumor DNA, microRNA, and radiomics may improve patient selection but require further validation. Clinical trials should prioritize translational research to address these challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2891","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:30:55Z","timestamp":1756999855000},"page":"1385","source":"Crossref","is-referenced-by-count":7,"title":["Current Controversies and Challenges in Non\u2013Oncogene-Addicted Synchronous Oligometastatic Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Mandy","family":"Jongbloed","sequence":"first","affiliation":[{"name":"Department of Pulmonary Diseases, GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bortolot","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Willmann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"},{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bartolomeo","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"},{"name":"Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Pavia University, Pavia, Italy"},{"name":"Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria M.","family":"Novoa","sequence":"additional","affiliation":[{"name":"Thoracic Surgery and Lung Transplantation Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk K. M.","family":"De Ruysscher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"crv250006r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"crv250006r2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012.","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"crv250006r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"crv250006r4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases.","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"18","key":"crv250006r5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv250006r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial.","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"crv250006r7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450).","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"crv250006r8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.","volume":"82","author":"Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"crv250006r9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2017.00210","article-title":"Radiotherapy for oligometastatic lung cancer.","volume":"7","author":"Bergsma","year":"2017","journal-title":"Front Oncol"},{"issue":"7","key":"crv250006r10","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.21037\/tlcr-21-58","article-title":"The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.","volume":"10","author":"Berzenji","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"crv250006r12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"crv250006r13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"crv250006r14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"crv250006r15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","article-title":"Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis.","volume":"109","author":"Rim","year":"2023","journal-title":"Int J Surg"},{"issue":"1","key":"crv250006r16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"crv250006r17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","article-title":"Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study.","volume":"168","author":"Willmann","year":"2022","journal-title":"Radiother Oncol"},{"issue":"5","key":"crv250006r18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of Oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline.","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"crv250006r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100667","article-title":"Brief report: long-term follow-up of adjuvant pembrolizumab after locally ablative therapy for oligometastatic NSCLC.","volume":"5","author":"Cantor","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"crv250006r20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer.","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"crv250006r21","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv250006r22","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","article-title":"Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR-5 trial.","volume":"118","author":"Baker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"crv250006r23","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.","volume":"14","author":"Giaj-Levra","year":"2019","journal-title":"J Thorac Oncol"},{"key":"crv250006r24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lungcan.2021.11.009","article-title":"Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.","volume":"164","author":"Boch","year":"2022","journal-title":"Lung Cancer"},{"issue":"9","key":"crv250006r25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state - separating truth from wishful thinking.","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"crv250006r26","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"issue":"7","key":"crv250006r27","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.21037\/tlcr-20-1065","article-title":"How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.","volume":"10","author":"Remon","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"crv250006r28","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy.","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"crv250006r29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors.","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"crv250006r30","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231183668","article-title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.","volume":"15","author":"Zayed","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"crv250006r31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ijrobp.2023.11.040","article-title":"Combining dual checkpoint immunotherapy with ablative radiation to all sites of oligometastatic non-small cell lung cancer: toxicity and efficacy results of a phase 1b trial.","volume":"118","author":"Bassetti","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"crv250006r32","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3390\/cancers16061174","article-title":"Long-term survival in patients with oligometastatic non-small cell lung cancer by a multimodality treatment\u2014comparison with stage III disease.","volume":"16","author":"Guberina","year":"2024","journal-title":"Cancers (Basel)"},{"key":"crv250006r33","doi-asserted-by":"publisher","first-page":"S895","DOI":"10.1016\/j.annonc.2020.08.1731","article-title":"1417TiP immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: the ETOP CHESS trial.","volume":"31","author":"Guckenberger","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"crv250006r34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects.","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"issue":"10","key":"crv250006r35","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/ijms22105123","article-title":"PD-1\/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects.","volume":"22","author":"Munari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"crv250006r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"crv250006r37","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227.","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv250006r38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial.","volume":"20","author":"Peters","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"4","key":"crv250006r39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"issue":"34","key":"crv250006r41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14694\/EdBook_AM.2014.34.3","article-title":"Cancer log-kill revisited.","author":"Norton","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"crv250006r42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-022-01879-3","article-title":"Steering decision making by terminology: oligometastatic versus argometastatic.","volume":"127","author":"Szturz","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"crv250006r44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijrobp.2020.12.044","article-title":"Revisiting a null hypothesis: exploring the parameters of oligometastasis treatment.","volume":"110","author":"Scarborough","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"crv250006r45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"crv250006r46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejca.2013.10.011","article-title":"The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.","volume":"50","author":"Liu","year":"2014","journal-title":"Eur J Cancer"},{"key":"crv250006r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103582","article-title":"PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.","volume":"170","author":"Deng","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"crv250006r48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.athoracsur.2024.01.024","article-title":"The emerging role of immunotherapy in resectable non-small cell lung cancer.","volume":"118","author":"Dunne","year":"2024","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"crv250006r49","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jtcvs.2023.09.048","article-title":"Surgery for oligometastatic non-small cell lung cancer.","volume":"167","author":"Antonoff","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"crv250006r50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-023-00440-6","article-title":"Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.","volume":"7","author":"Semenkovich","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"crv250006r51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semradonc.2023.03.004","article-title":"Emerging roles of circulating tumor DNA for increased precision and personalization in radiation oncology.","volume":"33","author":"Earland","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"crv250006r52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijrobp.2019.10.038","article-title":"Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: translational correlatives from a mature randomized phase II trial.","volume":"106","author":"Tang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7802","key":"crv250006r53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection.","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"issue":"13","key":"crv250006r54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/1759-7714.15281","article-title":"Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.","volume":"15","author":"Oh","year":"2024","journal-title":"Thorac Cancer"},{"key":"crv250006r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.","volume":"582","author":"Yang","year":"2024","journal-title":"Cancer Lett"},{"issue":"11","key":"crv250006r56","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"crv250006r57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"crv250006r58","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104619","article-title":"Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration.","volume":"209","author":"Fusco","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"crv250006r59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis.","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"crv250006r60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206108","article-title":"Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC.","volume":"13","author":"Dou","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"crv250006r61","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat Commun"},{"issue":"3","key":"crv250006r62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jtho.2016.11.2226","article-title":"Radiomic-based pathological response prediction from primary tumors and lymph nodes in NSCLC.","volume":"12","author":"Coroller","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"crv250006r63","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.radonc.2016.04.004","article-title":"Radiomic phenotype features predict pathological response in non-small cell lung cancer.","volume":"119","author":"Coroller","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"crv250006r64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.radonc.2015.02.015","article-title":"CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.","volume":"114","author":"Coroller","year":"2015","journal-title":"Radiother Oncol"},{"issue":"2","key":"crv250006r65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.radonc.2016.05.024","article-title":"CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer.","volume":"120","author":"Huynh","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"crv250006r66","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","article-title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.","volume":"20","author":"Lieverse","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"crv250006r67","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043628","article-title":"Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial.","volume":"11","author":"Tibdewal","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"crv250006r68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions.","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"crv250006r69","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","article-title":"Metastasis.","volume":"186","author":"Gerstberger","year":"2023","journal-title":"Cell"},{"issue":"12","key":"crv250006r70","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer\u2014a consensus report.","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"crv250006r71","doi-asserted-by":"publisher","first-page":"S2537","DOI":"10.21037\/jtd.2018.07.19","article-title":"The current state of oligometastatic and oligoprogressive non-small cell lung cancer.","volume":"10","author":"Tumati","year":"2018","journal-title":"J Thorac Dis"},{"issue":"7957","key":"crv250006r72","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","article-title":"Genomic-transcriptomic evolution in lung cancer and metastasis.","volume":"616","author":"Mart\u00ednez-Ruiz","year":"2023","journal-title":"Nature"},{"issue":"7","key":"crv250006r73","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.21037\/tlcr-20-1134","article-title":"A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.","volume":"10","author":"Belluomini","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"crv250006r74","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.ccell.2023.03.018","article-title":"Genomic mapping of metastatic organotropism in lung adenocarcinoma.","volume":"41","author":"Lengel","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"crv250006r75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"issue":"10","key":"crv250006r76","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"crv250006r77","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PPO.0000000000000202","article-title":"Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management.","volume":"22","author":"Correa","year":"2016","journal-title":"Cancer J"},{"issue":"12","key":"crv250006r78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050141","article-title":"Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.","volume":"7","author":"Lussier","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"crv250006r79","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.3892\/ol.2018.9464","article-title":"Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small-cell lung cancer.","volume":"16","author":"Aiso","year":"2018","journal-title":"Oncol Lett"},{"issue":"7","key":"crv250006r80","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.21037\/tlcr-21-448","article-title":"Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.","volume":"10","author":"Rashdan","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"crv250006r81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028650","article-title":"MicroRNA expression characterizes oligometastasis(es).","volume":"6","author":"Lussier","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"crv250006r82","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010958","article-title":"Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients.","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"crv250006r83","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited.","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"crv250006r84","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer.","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"crv250006r43","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/978-3-642-16483-5_4130","volume-title":"Encyclopedia of Cancer","author":"Traina","year":"2011"},{"key":"crv250006r11","unstructured":"National Comprehensive Cancer Network. Non-small Cell Lung Cancer. Version 10.2024. Accessed September 29, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"crv250006r40","unstructured":"Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (ICARS). ClinicalTrials.gov identifier: NCT06219317. Updated July 16, 2025. Accessed May 14, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06219317"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2838531\/jamaoncology_jongbloed_2025_rv_250006_1763138446.81455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:04:09Z","timestamp":1763654649000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2838531"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2891","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}